Navigation Links
SF1126, Semafore's PI3 Kinase Inhibitor, Found to Block Angiogenic Signaling From Both VEGF and Bv8 in Multiple Cell Lines
Date:8/26/2008

INDIANAPOLIS, Aug. 26 /PRNewswire/ -- Semafore Pharmaceuticals Inc. announced data presented at the Seventh International Congress on Targeted Therapies in Cancer in Washington, D.C., showing additional antiangiogenic activity of vascular-targeted PI3 kinase (PI3K) inhibitor SF1126, by blocking both VEGF and Bv8 signaling.

PI3K is part of a very powerful pathway, the PI3/AKT /mTOR pathway that has been shown to play a major role in cancer. Studies have shown that by inhibiting this pathway, tumor growth can be suppressed.

SF1126, a vascular targeted pan-PI3K inhibitor conjugate currently in Phase I clinical trials, was shown to block the pAKT pathway through which the angiogenic factors VEGF and Bv8 are involved. Bv8 is a recently identified protein that, like VEGF, plays a role in the angiogenic process and can significantly upregulate pAKT levels thereby supporting tumor growth.

In vitro inhibition of the PI3K/AKT/mTOR pathway by SF1126 was demonstrated to impede the ability of angiogenic stimulants VEGF and Bv8 to activate AKT in a dose dependant manner in two cancer cell lines (786-0 -- renal cell and PC3 prostate) and one endothelial cell line (HBEC -- human brain endothelial cells). Inhibiting Bv8 with antibodies has also been shown by others to have antitumor effects in mouse xenograft models.

"SF1126 could have additional impact in treating cancer where Bv8 is an important component of angiogenesis," said Dr. Dennis McKeever, Semafore's Chief Executive Officer. "In addition to targeting angiogenesis, SF1126 blocks key targets involved in tumor growth including mTOR, DNA-PK, PIM-1 and PLK-1. This adds another layer of versatility to what SF1126 can do as an antitumor agent."

About Semafore

Semafore is a clinical stage drug discovery and development company focused on small molecule modulators of the PI3 kinase and PTEN cell signaling pathway, a promising target pathway for multiple disorders, including the comp
'/>"/>

SOURCE Semafore Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Semafore Pharmaceuticals Reports Positive Interim Results from a Phase I Study of SF1126, a Targeted Pan-PI3K Inhibitor, in Patients with Advanced Solid Tumors
2. Telik Announces Presentation of Preclinical Data on Dual Inhibitors of Aurora Kinases and VEGFR2
3. Telik Announces Preclinical Data Demonstrating Anti-Cancer Activity of Dual Inhibitors of Aurora Kinase and VEGFR2
4. Semafores PI3 Kinase Inhibitor SF1126 is Active Against Tumor and Tumor Cells and Synergizes with Standard Chemotherapy Agents
5. SuperGen Reports Initiation of Multi-arm Phase 1b Trial of Novel Tyrosine Kinase Inhibitor
6. EntreMed to Highlight ENMD-2076 Kinase Inhibitor at 2008 AACR Annual Meeting
7. Semafores PI3 Kinase Inhibitor SF1126 is a Vascular Targeted Conjugate in Phase I Clinical Trials in Solid Tumors and Multiple Myeloma
8. Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors
9. SuperGen Identifies Lead PIM Kinase Inhibitor, SGI-1776, That Causes Tumor Regression in AML Xenograft Models
10. Latest Cell Publication Describes the Novel Kinase Regulators Using OriGenes Functional Kinome Collection
11. Poniard Pharmaceuticals Licenses Kinase Inhibitors From The Scripps Research Institute
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... Calif. , July 28, 2014  Isis Pharmaceuticals, ... webcast:What:Isis Pharmaceuticals, Second Quarter 2014 Financial Results and Highlights ... 7:30 a.m. PTWhere: www.isispharm.com How:Live on the Internet. ... are unable to participate during the live event, a ... limited time at www.isispharm.com . ABOUT ...
(Date:7/28/2014)... , July 28, 2014 CTI BioPharma Corp. ... will report its second quarter 2014 financial results on ... U.S. financial markets. Following the announcement, members of the ... discuss the results and provide a general corporate update ... the event can be obtained as follows: ...
(Date:7/25/2014)... , July 25, 2014  In today,s marketplace, ... costly and challenging - as is managing a portfolio ... Is it possible - or even preferable - ... so, where can you combine resources and activities, and ... These are just a few of the ...
Breaking Medicine Technology:Webcast Alert: Isis Pharmaceuticals' Second Quarter 2014 Financial Results Conference Call 2CTI BioPharma to Report Second Quarter 2014 Financial Results on August 4, 2014 2Using Promotional Efficiency to Support Multiple Products and Indications in the Pharmaceutical Marketplace 2
... DIA and the National Pharmaceutical Council (NPC) ... User,s Guide  Conference on March 14-15 at the ... will focus on the continued push for increased ... applied within health technology assessments, research planning and ...
... 2012 PhotoVoltaic Solar Cells, Inc. (OTCBB: PVSO) ... February 27, 2012, it completed a share exchange ... focused on developing and commercializing proprietary clinical diagnostic ... as well as companion therapeutics to prevent systemic ...
Cached Medicine Technology:DIA and National Pharmaceutical Council Will Host Two-Day Conference on Comparative Effectiveness Research 2PhotoVoltaic Solar Cells, Inc. Completes Share Exchange with MetaStat, Inc. 2PhotoVoltaic Solar Cells, Inc. Completes Share Exchange with MetaStat, Inc. 3PhotoVoltaic Solar Cells, Inc. Completes Share Exchange with MetaStat, Inc. 4
(Date:7/28/2014)... into improving treatment for patients with one of the ... funding boost. , Chronic obstructive pulmonary disease (COPD) is ... breathing difficulties due to long-term damage to the lungs. ... 10 per cent of all hospital admissions in the ... to hospital after they are discharged. , ...
(Date:7/28/2014)... The report “Industrial Enzymes Market by Types (Carbohydrase, ... Bio-Fuel, Animal Feed), & Geography - Global Trends ... global industrial enzymes market with analysis and forecasting ... also identifies driving and restraining factors for the ... opportunities, burning issues, winning imperatives, and challenges. The ...
(Date:7/28/2014)... 28, 2014 The Wireline Services Market in ... Europe with analysis and forecast of revenue. The Wireline services ... billion in 2013 to $2.4 billion by 2019, at a ... the TOC of the Wireline Services Market in Europe report, ... also provides a glimpse of the segmentation in the European ...
(Date:7/28/2014)... 2014 (HealthDay News) -- People with higher levels of ... diabetes, a new study suggests. Unlike white fat, ... actually improves insulin sensitivity, blood sugar control and fat-burning ... obese people," Labros Sidossis, a professor of internal medicine ... of Texas Medical Branch at Galveston, said in ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 In response ... Americans face today, BlogHer, The Center for American Progress ... “Make Life Work,” a campaign to raise awareness and ... across the U.S. The joint initiative was announced on ... Editor-in-Chief, BlogHer; Judith Warner, Senior Fellow, The Center for ...
Breaking Medicine News(10 mins):Health News:New research to tackle treatment for lung disease 2Health News:New research to tackle treatment for lung disease 3Health News:Industrial Enzymes Market Worth $5,987.5 Million by 2018 - Report by MarketsandMarkets 2Health News:Industrial Enzymes Market Worth $5,987.5 Million by 2018 - Report by MarketsandMarkets 3Health News:Industrial Enzymes Market Worth $5,987.5 Million by 2018 - Report by MarketsandMarkets 4Health News:Europe Wireline Services Market is Expected to Reach $2.4 billion in 2019 - New Report by MicroMarket Monitor 2Health News:Europe Wireline Services Market is Expected to Reach $2.4 billion in 2019 - New Report by MicroMarket Monitor 3Health News:Europe Wireline Services Market is Expected to Reach $2.4 billion in 2019 - New Report by MicroMarket Monitor 4Health News:Healthy 'Brown Fat' May Cut Odds for Obesity, Diabetes 2Health News:“Make Life Work” Campaign Launches to Address the Needs of Today's Working Families & Promote Realistic Solution 2Health News:“Make Life Work” Campaign Launches to Address the Needs of Today's Working Families & Promote Realistic Solution 3Health News:“Make Life Work” Campaign Launches to Address the Needs of Today's Working Families & Promote Realistic Solution 4Health News:“Make Life Work” Campaign Launches to Address the Needs of Today's Working Families & Promote Realistic Solution 5
... ... , ... 2010 -- Blue Cross Blue Shield of Massachusetts, Inc. (BCBSMA) and Northeast Health ... Quality Contract (AQC). The agreement marks the first North Shore physician group to adopt ...
... drugs before surgery let even high-risk women opt for ... breast cancer patients estrogen-lowering drugs before surgery enhances their ... instead of a full mastectomy, new research suggests. , ... at 118 hospitals across the United States. It focused ...
... ... A new iPhone App from Thinklabs provides everyone from ... for learning or classifying patient heart sounds. iMurmur 2 includes digital ... follows the release of Stethoscope App by Thinklabs, a complete clinical ...
... ... assembly, you can effectively block up to 90% of the unwanted noise bleeding through a common ... live, play, sleep or work in peace and quiet! , ... (PRWEB) May 25, 2010 -- Isolating one room,s noise from the next through ...
... themselves, consider suicide, study finds , TUESDAY, May 25 ... rare but disabling psychiatric disorder known as olfactory reference ... horrible smells and, as a result, often isolate themselves ... a result of this false belief, and they appear ...
... the Cleveland Clinic finds that patients suffering from cirrhosis ... of developing hepatocellular carcinoma than those who develop cirrhosis ... this study appear in the June issue of ... of the American Association for the Study of Liver ...
Cached Medicine News:Health News:Blue Cross Blue Shield of Massachusetts and Northeast Health Systems Physician Hospital Organization Sign Alternative Quality Contract 2Health News:Blue Cross Blue Shield of Massachusetts and Northeast Health Systems Physician Hospital Organization Sign Alternative Quality Contract 3Health News:Blue Cross Blue Shield of Massachusetts and Northeast Health Systems Physician Hospital Organization Sign Alternative Quality Contract 4Health News:Breast Cancer Study Offers New Hope 2Health News:Hearing Everything in a Heartbeat - New Heart Murmur App 2Health News:Hearing Everything in a Heartbeat - New Heart Murmur App 3Health News:Share Your Walls, Not the Noise. Introducing dB-Bloc for Common Wall Sound Bleed 2Health News:Rare Disorder Has People Convinced They Smell Bad 2Health News:Rare Disorder Has People Convinced They Smell Bad 3Health News:New study confirms link between nonalcoholic steatohepatitis and liver cancer 2Health News:New study confirms link between nonalcoholic steatohepatitis and liver cancer 3
... from Thermo Labsystems was designed specifically to ... features such as the new fast dial ... microvolumes help to define this as a ... new interchangeable handle plate offers a custom ...
Research® Series 2100 Adjustable-volume Pipette, 0.5-10 µl, single-channel with adjustable-volume setting...
This CLS number is a new product number, created to easily match Cornings product number. If showing no availability yet, please order under the old Sigma-Aldrich number (Z71,412-7) or contact custom...
... Series 2000 Pipette is a synonym for ... and robust design, and superior operating comfort. ... operate the measuring stroke and blow-out as ... features: Eppendorf "pipette/tip" system ensures utmost ...
Medicine Products: